Synaptic Acid Encapsulated with Selenium-Mesoporous Silica Nanocomposite: A Potential Drug in Treating Cardiovascular Disease

The development of multifunctional nanomaterials can greatly improve therapeutic efficacy in treating disease. In this present study, we report a new class of drug delivery system to maximize the therapeutic potential in treating cardiovascular disease. Synaptic acid encapsulated selenium-mesoporous silica (SA-PSiO2-SeNDs-PEG) nanocomposite was synthesized via the conjugation of synaptic acid (SA) with encapsulated selenium-mesoporous silica. This nanocomposite showed a more stable and sustainable SA release capacity in the delivery system. Furthermore, the treatment of SA-PSiO2-SeNDs-PEG nanocomposite reduced the reactive oxygen species (ROS) stress via the 2 ', 7 '-dichlorofluorescein diacetate (DCFH-DA) fluorescence intensity measurements in vitro. Furthermore, serum content analysis revealed a drop in the low-density lipoprotein level. The histological analysis resulted in no morphological difference in the mice tissue section treated with SA-PSiO2-SeNDs-PEG nanocomposite as compared to the mice treated with saline solution, signifying no side effects occurred using this drug delivery platform. In short, SA-PSiO2-SeNDs-PEG nanocomposite are novel drug delivery platforms that will be potentiating the treatment of cardiovascular disease with more insights that are elucidated.

Automated summary

A new drug delivery system using a nanocomposite was developed to enhance therapeutic potential in treating cardiovascular disease. The stable and sustainable drug release capacity of the nanocomposite reduced reactive oxygen species stress and showed promising effects in lowering low-density lipoprotein levels. Overall, this novel drug delivery platform exhibited no side effects and has the potential to improve treatment outcomes for cardiovascular disease.